The role of Central Venous Catheters (CVC) is significant for the End-Stage Renal Disease (ESRD) population. The placement of the CVC for a HD (HD) patient is not only necessary, but life-sustaining. CVCs are usually placed for an emergent HD treatment, while awaiting a permanently placed arteriovenous fistula or graft (AVF/AVG), or when the permanent access becomes non-functioning. There are multiple risk factors related to having a CVC placed, the most predominant complication being catheter line-associated bloodstream infections (CLABSIs). Studies have shown that implementing a CVC prevention bundle was associated with a significant reduction in the CLABSI rates within the HD population. Implementing and examining the efficacy of best evidence-based practices to determine whether infection rates decrease in the ESRD population with a prevention bundle intervention, was the aim of this integrative review. Having the ability to control infection in ESRD patients is a challenging task for healthcare providers, especially because catheters are often manipulated during HD treatments, and ESRD patients are already immunocompromised
